Bottom of Form Microparticulate drug delivery systems have shown a good interest within the pharmaceutical space. they permit the rise of drug therapeutic effectiveness and therefore the reduction of aspect effects. during this context, microsponges represent a brand new model of porous uu microspheres, which permit the defense of a good vary of active agents. Microsponge drug delivery system (MDS) was developed to deliver the pharmaceutical ingredients efficiently at the positioning of administration at a restricted dose. MDS is predicated on pore size of sponges. The action of microsponges lasts up to 12 hours. A microsponge's delivery system could be a extremely cross-linked, porous, chemical compound microsphere, chemical compound system consisting of porous microspheres that may entrap and unleash them into the skin over long amount. This delivery system provides extended release with reduced irritation, higher tolerance, improved thermal, physical and chemical stability. Microsponges area unit ready by many technique utilization emulsion system or by suspension chemical process into a liquid-liquid system. Microsponges will entrapped numerous style of drug and incorporated in formulation like cream, powder, gels, and lotions. Topical preparation have some disadvantages like unpleasant odour, oiliness and skin irritation and fail to achieve the circulation this drawback is overcome by microsponges delivery system.
Cite this article:
S. D Mankar, Mahale Gayatri. Review on Microsponges a Novel Drug Delivery System. Asian Journal of Pharmaceutical Research. 2022; 12(3):241-8. doi: 10.52711/2231-5691.2022.00040
S. D Mankar, Mahale Gayatri. Review on Microsponges a Novel Drug Delivery System. Asian Journal of Pharmaceutical Research. 2022; 12(3):241-8. doi: 10.52711/2231-5691.2022.00040 Available on: https://www.asianjpr.com/AbstractView.aspx?PID=2022-12-3-11
1. Aloorkar NH, Kulkarni a S, Ingale DJ, Patil R a. Microsponges as innovative drug delivery systems. Int J Pharm Sci Nanotechnol 2012;5
2. Patel UB, Patel HM, Shah CN, A review- Recent research on microsponge a novel new drug delivery system, International Journal of Advances in Pharmaceutics, 2018; 07 (03): 10-16
3. Patil RS, Kemkar VU, Patil SS. Microsponge drug delivery system: a novel dosage form. Am J PharmTech Res. 2012; 2:227–51.
4. Trotta F, Cavalli R, Tumiatti W. Cyclodextrin-based nanosponges fordrug delivery. J Inc Phenom Macrocyclic Chem 2006; 56:209-13.
5. Angamuthu M, Nanjappa SH, Raman V, Jo S, Cegu P, MurthySN. Controlled-release injectable containing terbinafine/ PLGA microspheres for onychomycosis treatment. J Pharm Sci.2014;103(4):1178–83.
6. Sagavkar SR and Mohit SK: Innovative and novel strategy: Microsponges drug delivery system. International Journal of Universal Pharmacy and Biosciences 2014; 3(4)7)
7. Rajurkar VG, Tambe AB and Deshmukh VK: Topical anti-inflammatory gels of naproxen entrapped in eudragit based microsponge delivery system. Journal of Advanced Chemical Engineering. 2015; 5(2): 2-6
8. Nawal A and Mohammad S: Formulation and in-vitro evaluation of piroxicam microsponge as a tablet. International Journal of Pharmacy and Pharmaceutical Sciences. 2016; 8(2): 104-11.
9. Bhumika Sharma, Arvind Sharma. Future prospect of nanotechnology in development of anti-ageing formulations. Int J Pharm Pharm Sci, 4(3), 2012, 57-66.
10. Sarat C. P. M., Ajay M., Nagendra B.B., Prathyusha P., Audinarayana N., Bhaskar R.K. Microsponge Drug Delivery System. A Review. J. Pharm. Res. 2011; 4(5): 1381-1384.
11. D‟souza JI. In-vitro Antibacterial and Skin Irritation Studies of Microsponges of Benzoyl Peroxide. Indian Drugs. 2001, 38(7): 23.
12. Khopade AJ, Jain S, Jain NK. The Microsponge. East Pharm. 1996; 39:49-53.
13. John I. D'souza, Jagdish K. Saboji, Suresh G. Killedar, Harinath N. More “Design and Evaluation of Benzoyl Peroxide Microsponges to Enhance Therapeutic Efficacy in Acne Treatment”, Accepted for presentation in 20th FAPA Congress, Bangkok, Thailand, Nov Dec 3, 200428
14. Pawar AP, Gholap AP, Kuchekar AB, Bothiraja C, Mali AJ. Formulation and evaluation of optimized oxybenzone microsponge gel for topical delivery. J Drug Deliv. 2015; 2015:261068. doi: 10.1155/2015/261068.
15. Salwa S, Ghada EAA, Makhlouf AIA. Improved vaginal retention and enhanced antifungal activity of miconazole microsponges gel, formulation development and in vivo therapeutic efficacy in rats. EJPS. 2018;114:255–266.
16. Bruschi, M. L. 2015. Strategies to modify the drug release from pharmaceutical systems, Woodhead Publishing.
17. Moin, A., Deb, T. K., Osmani, R. A. M., Bhosale, R. R. and Hani, U. 2016. Fabrication, characterization, and evaluation of microspongedelivery system for facilitated fungal therapy. J Basic Clin Pharm., 7, 39.
18. Orlu, M., Cevher, E. and Araman, A. 2006. Design and evaluation of colon specific drug delivery system containing flurbiprofen microsponges. Int J Pharm, 318, 103-117
19. Singhvi, G., Manchanda, P., Hans, N., Dubey, S. K. & Gupta, G. 2019. Microsponge: an emerging drug delivery strategy. Drug Develop Res, 80, 200-208.
20. Khopade AJ, Jain S, Jain NK. The Microsponge. East Pharm 1996; 39:49-53
21. Barde PM, Basarkar GD. Formulation, development and invitro evaluation of terbinafine HCl microsponge gel. Int Pharm Sci Rev Res 2015; 32:310–14
22. Date AA, Naik B, Nagarsenker MS. Novel drug delivery systems: potential in improving topical delivery of antiacne agents. Skin Pharmacol Physiol 2006;19(1):2–16.
23. Billow JA. Acne products. Handbook of non-prescription drugs. 8th ed. Washington: DC: APhA; 1986.
24. Ameen M. Epidemiology of superficial fungal infections. Clin Dermatol 2010;28(2):197–201.
25. Gennaro AR. Remington: The Science and Practice of Pharmacy. Baltimore, M.D.: Lippincott Williams and Wilkins;2000
26. Lesher JL Jr. Oral therapy of common superficial Fungal infections of the skin. J Am Acad Dermatol1999;40: S31–4.
27. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous leishmaniasis. Lancet Infect Dis. 2007; 7:581–96.
28. Shah CN, Shah DP. Design and optimization of fluconazoleMicrosponges containing ethyl cellulose for topical deliverySystem using quality by design approach. Pharma ScienceMonitor 2014; 5:95–133.
29. Moin A, Deb TK, Osmani RA, Bhosale RR, Hani U. Fabrication, characterization, and evaluation of microsponge delivery system for facilitated fungal therapy. J Basic Clin Pharm 2016;7(2):39
30. Zaki Rizkalla CM, Latif Aziz R, Soliman II. In vitro and In vivo evaluation of hydroxyzine hydrochloride Microsponges for topical delivery. AAPS Pharm Sci Tech 2011; 12:989–1001.
31. Barzic AI, Ioan S. Antibacterial drugs – From basic concepts to complex therapeutic mechanisms of polymer systems. In: Bobbarala V, editor. Concepts, compounds and the Alternatives of antibacterials. London: InTech Open; 2015.Doi:10.5772/60755
32. Conly JM, Johnston BL. Mupirocin – are we in danger of Losing it? Can J Infect Dis Med Microbiol 2002;13(3):157–9.
33. Parenti MA, Hatfield SM, Leyden JJ. Mupirocin: a topical Antibiotic with a unique structure and mechanism ofAction. Clin Pharm 1987;6(10):761–70.
34. Wadhwa G, Kumar S, Mittal V, Rao R. Encapsulation of Babchi essential oil into microsponges: physicochemicalProperties, cytotoxic evaluation and anti-microbial activity. J Food Drug Anal 2018. Doi: 10.1016/j.jfda.2018.07.006
35. Fulton JE, Farzad-Bakshandeh A, Bradley S. Studies on the mechanism of action of topical benzoyl peroxide in acne vulgaris. J Cutan Pathol 1974; 1:191–200
36. Kumar PM, Ghosh A. Development and evaluation of silver sulfadiazine loaded microsponge based gel for partial thickness (second degree) burn wounds. Eur J Pharm Sci 2017; 96:243–54
37. Tejashri G, Amrita B, Darshana J. Cyclodextrin based nanosponges for pharmaceutical use: a review. Acta Pharm. 2013; 63(3): 335–58
38. Kumar S, Pooja, Trotta F, Rao R. Encapsulation of babchi oil in cyclodextrin-based nanosponges: physicochemical characterization, photodegradation, and in vitro cytotoxicity studies. Pharmaceutics. 2018;10(4):169.